New drug interaction study in healthy men
NCT ID NCT02783040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study looked at how the experimental drug BI 425809 (iclepertin) changes the way the body processes four common medications: midazolam, warfarin, omeprazole, and digoxin. Thirteen healthy men took these drugs with and without BI 425809 to see if there were any interactions. The goal was to gather safety and dosing information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iclepertin (BI 425809)
- What this could lead to
- If successful, this study will help doctors understand how to safely combine BI 425809 with other common drugs.
- What could go wrong
- This is a very early, small study in healthy men, not patients. It only measures drug levels, not any treatment effect. Results may not apply to women or sick people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
1346.22.1 Boehringer Ingelheim Investigational Site
Biberach, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test